Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...
Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...
BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma ...
Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.
Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.
"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. As global markets navigate a mixed economic landscape marked by declining ...
(Guy Leblanc/Radio-Canada ) All three New Brunswick clinics are owned by Grifols, a Spanish multinational pharmaceutical and chemical manufacturer, formerly known as Canadian Plasma Resources.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
US short seller Gotham City Research asked a judge in New York to dismiss a lawsuit accusing it of conspiring to drive down shares in Grifols SA. The drug maker’s market capitalization has ...
That is below Grifols' current share price of around €11, and well shy of its near-€15 share price at the start of the year, ahead of a campaign by hedge fund Gotham City Research, which ...
Spanish firm Grifols (MCE: GRF) has submitted a Biologics License Application ... It’s part of the key information for keeping me informed ...
‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and ...